{
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3819, 
        3833
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3941, 
        3961
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3723, 
        3750
      ]
    }
  ], 
  "Lymphatic System Location (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2332, 
        2333
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        794, 
        823
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2344, 
        2379
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2134, 
        2160
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3799, 
        3808
      ]
    }
  ], 
  "Neoplasm Grade-Score Name (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3835, 
        3842
      ]
    }
  ], 
  "Neoplasm Score Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3855, 
        3856
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2165, 
        2173
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2189, 
        2197
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2212, 
        2220
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2236, 
        2244
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2260, 
        2268
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2283, 
        2291
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3809, 
        3818
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2174, 
        2181
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2198, 
        2204
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2221, 
        2228
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2245, 
        2252
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2269, 
        2275
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2292, 
        2299
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2162, 
        2163
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2186, 
        2187
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2209, 
        2210
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2233, 
        2234
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2257, 
        2258
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2280, 
        2281
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PATHLAB_LIS|HOSPITAL 9^9999^MOH|PIMS|CCO|20160505113613|3E18C547BF5DED0B84DE9E9D925F997EA5ACD161|ORU^R01|99999999999999999999|P|2.5|\nPID|1||M999999999^^^^CMR^HOSPITAL&9999&MOH~M999999999^^^^^HOSPITAL&9999&MOH~M999999999^^^^MRN^HOSPITAL&9999&MOH~9999999999&AW&ON^^^^JHN||XXXXXXX^XXXX^XXXXXX||99999999|M|||99 XXXX XXXX XXXXX^^XXXXXXXXXXX^XX^X9X 9X9^999||9999999999^AW^OHIN|||||5925278292^AW^OHIN||||||||||||N|\nOBR|1||QCS1606703|11529-5^Surgical Pathology Study Report^LN^P^Pathology^L|||20160504091500|||70260^XXXXXXXXX^XXXXXX^^^^XX||||20160504131401|Prostate RT Base x 2&Prostate RT Mid x 2&Prostate RT Apex x 2&Prostate LT Base x 2&Prostate LT Mid x 2&Prostate LT Apex x 2|999999^XXXXXXXXX^XXXXXX^^^^XX||||N|20082009|20160505113613|||F|||||||99999^XXXXX^XXXXXXXXX^^^^XX, XXXXX|\n\n\n\n\n\n\n\nPath report.gross description\n\n1. The specimen is received in a container of formalin labeled with the patient's name, whose initials are \"PB\", and \"prostate right base\".\nNumber of fragments: 2\nDimensions: 1.4 and 1.6 cm\nOther: nil\n1A - in toto\n2. The specimen is received in a container of formalin labeled with the patient's name, whose initials are \"PB\", and \"prostate right mid\".\nNumber of fragments: 2\nDimensions: Each 1.6 cm\nOther: nil\n2A - in toto\n3. The specimen is received in a container of formalin labeled with the patient's name, whose initials are \"PB\", and \"prostate right apex\".\nNumber of fragments: 2\nDimensions: Each 1.5 cm\nOther: nil\n3A - in toto\n4. The specimen is received in a container of formalin labeled with the patient's name, whose initials are \"PB\", and \"prostate left base\".\nNumber of fragments: 2\nDimensions: 1.5 and 1.8 cm\nOther: nil\n4A - in toto\n5. The specimen is received in a container of formalin labeled with the patient's name, whose initials are \"PB\", and \"prostate left mid\".\nNumber of fragments: 2\nDimensions: 1.5 and 2.0 cm\nOther: nil\n5A - , in toto\n6. The specimen is received in a container of formalin labeled with the patient's name, whose initials are \"PB\", and \"prostate left apex\".\nNumber of fragments: 2\nDimensions: 1.6 and 1.9 cm\nOther: nil\n6A -in toto\nDP, HOSPITAL, 04/05/2016 2:11 PM\n\n\nPath report.site of origin\n\n1. Prostate RT Base x 2\n2. Prostate RT Mid x 2\n3. Prostate RT Apex x 2\n4. Prostate LT Base x 2\n5. Prostate LT Mid x 2\n6. Prostate LT Apex x 2\nClinical Information: PSA 8.9\n#1-6-x2\n\n\nPath report.microscopic observation\n\nPROSTATE CORE NEEDLE BIOPSY TEMPLATE\nHistologic Type: Prostatic adenocarcinoma\nSpecimen 1, Right base         Gleason grade: 3+4 = 7/10\nNumber cores involved / total number cores: 2/2\nPercentage of each core involved by tumour: 75% and 75%\nSpecimen 2, Right mid          Gleason grade: 3+4 = 7/10\nNumber cores involved / total number cores: 2/2\nPercentage of each core involved by tumour: 75% and 50%\nSpecimen 3, Right apex         Gleason grade: 3+4 = 7/10\nNumber cores involved / total number cores: 2/2\nPercentage of each core involved by tumour: 60% and 40%\nSpecimen 4, Left base          Gleason grade:  N/A\nNumber cores involved / total number cores:  0/2\nPercentage of each core involved by tumour: N/A\nSpecimen 5, Left mid            Gleason grade:  N/A\nNumber cores involved / total number cores:  0/2\nPercentage of each core involved by tumour: N/A\nSpecimen 6, Left apex           Gleason grade: 3+3 = 6/10\nNumber cores involved / total number cores: 1/2\nPercentage of each core involved by tumour: 5%\nPeriprostatic Fat Invasion:  Not identified\nSeminal Vesicle Invasion:  Not identified\nPerineural Invasion: Present in the right mid zone\nLymphatic (Small Vessel) Invasion:  Not identified\nAdditional Pathologic Findings: The Gleason pattern 4 makes up approximately 10% of the tumor are identified within these biopsy fragments.\n\n\nPath report.final diagnosis\n\n1-6. Prostate, sextet needle core biopsies:\n-- Bilateral prostatic adenocarcinoma, Gleason grade 3+4 = 7/10 (ISUP Grade Group 2)\n-- 7/12 cores involved\n-- Right-sided perineural invasion\n\n\nPath report.comments\n\nIn accordance with the Quality Assurance Program in the Department of Pathology at the Queensway Carleton HOSPITAL, selected slides have been reviewed by a second pathologist, Dr. B. Gannon, who agrees with the diagnosis of malignancy.\n\n\n"
}